A phase Ib study of BKM120 and trastuzumab (a HER2 antibody) in patients with HER2+ or trastuzumab-resistant breast cancer demonstrates that this combination is generally well-tolerated and it inhibits activation of both PI3K/Akt and ERK pathways [112]. This evidence concerns the gene AKT1 and breast cancer.